Xenon Pharmaceuticals Inc. financials
Key figures from Xenon Pharmaceuticals Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net income | -$111M | -$85M | -30.7% |
| Free cash flow | -$96M | -$64M | -48.6% |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $8M | -$346M | -4612.1% | -$280M | -$4.36 |
| FY Dec 2024 | $0 | -$234M | — | -$184M | -$3.01 |
| FY Dec 2023 | $0 | -$182M | — | -$157M | -$2.73 |
| FY Dec 2022 | $9M | -$125M | -1328.9% | -$104M | -$2.06 |
| FY Dec 2021 | $18M | -$79M | -427.8% | -$72M | -$1.77 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.